Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
27.45
Dollar change
-0.02
Percentage change
-0.07
%
IndexRUT P/E- EPS (ttm)-2.95 Insider Own11.27% Shs Outstand95.64M Perf Week-6.95%
Market Cap2.63B Forward P/E- EPS next Y-3.35 Insider Trans-3.96% Shs Float84.86M Perf Month15.19%
Income-228.68M PEG- EPS next Q-0.78 Inst Own91.76% Short Float13.42% Perf Quarter89.18%
Sales10.87M P/S241.52 EPS this Y-8.78% Inst Trans-0.74% Short Ratio9.29 Perf Half Y343.46%
Book/sh8.69 P/B3.16 EPS next Y-5.75% ROA-29.22% Short Interest11.39M Perf Year142.71%
Cash/sh9.58 P/C2.87 EPS next 5Y- ROE-32.91% 52W Range4.82 - 30.84 Perf YTD203.31%
Dividend Est.- P/FCF- EPS past 5Y-57.60% ROI-27.34% 52W High-10.99% Beta0.81
Dividend TTM- Quick Ratio12.47 Sales past 5Y148.90% Gross Margin64.89% 52W Low468.91% ATR (14)1.57
Dividend Ex-Date- Current Ratio12.47 EPS Y/Y TTM12.25% Oper. Margin-2347.64% RSI (14)53.35 Volatility5.62% 5.78%
Employees253 Debt/Eq0.01 Sales Y/Y TTM12.50% Profit Margin-2103.78% Recom1.00 Target Price45.25
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-6.13% Payout- Rel Volume0.54 Prev Close27.47
Sales Surprise36.18% EPS Surprise0.77% Sales Q/Q58.67% EarningsMay 09 AMC Avg Volume1.23M Price27.45
SMA201.60% SMA507.63% SMA200105.89% Trades Volume658,359 Change-0.07%
Date Action Analyst Rating Change Price Target Change
May-03-24Initiated BofA Securities Buy $40
Mar-14-24Initiated Cantor Fitzgerald Overweight $60
May-22-23Upgrade Evercore ISI In-line → Outperform $20
Mar-31-23Downgrade Evercore ISI Outperform → In-line $20
Jul-20-22Initiated Chardan Capital Markets Buy $29
Jul-12-22Initiated Raymond James Strong Buy $29
Sep-07-21Initiated Evercore ISI Outperform $50
Jun-17-21Initiated Needham Buy $50
Apr-26-21Resumed Credit Suisse Outperform $37
Jul-07-20Initiated Wells Fargo Overweight $60
May-23-24 06:00AM
May-21-24 04:05PM
May-19-24 09:03AM
May-17-24 03:24AM
May-15-24 09:00AM
11:55PM Loading…
May-09-24 11:55PM
04:05PM
May-08-24 04:05PM
12:27PM
06:00AM
Apr-22-24 04:05PM
Apr-04-24 01:30AM
Mar-27-24 09:00AM
Mar-21-24 04:05PM
Mar-15-24 07:01PM
04:02PM Loading…
Mar-04-24 04:02PM
07:00AM
Feb-29-24 12:00PM
07:00AM
Feb-28-24 05:20PM
04:40PM
04:05PM
Feb-27-24 09:00AM
Feb-26-24 06:55AM
Feb-21-24 04:05PM
Feb-20-24 09:00AM
Feb-15-24 05:00PM
Jan-29-24 08:54AM
Jan-22-24 04:05PM
Jan-05-24 08:30AM
04:05PM Loading…
Dec-21-23 04:05PM
Dec-13-23 08:30AM
Nov-29-23 09:03AM
Nov-28-23 10:09AM
10:02AM
07:01AM
06:30AM
Nov-21-23 04:05PM
09:00AM
Nov-08-23 06:12PM
04:05PM
Oct-23-23 04:05PM
Oct-07-23 07:30AM
Sep-26-23 09:00AM
Sep-25-23 09:00AM
Sep-21-23 04:05PM
Sep-11-23 07:28PM
Sep-07-23 09:00AM
Aug-31-23 09:00AM
Aug-30-23 09:00AM
Aug-21-23 04:05PM
Aug-15-23 09:00AM
Aug-08-23 07:15PM
04:05PM
Jul-21-23 04:05PM
Jul-12-23 07:24AM
Jun-21-23 04:05PM
Jun-20-23 09:00AM
Jun-08-23 09:00AM
May-22-23 04:05PM
May-17-23 12:38PM
07:00AM
May-09-23 06:15PM
04:05PM
May-04-23 09:00PM
Apr-28-23 10:08AM
Apr-27-23 03:40PM
Apr-24-23 09:00AM
Apr-21-23 04:05PM
Apr-17-23 09:00AM
Apr-13-23 09:00AM
Apr-11-23 11:23AM
Apr-05-23 10:14AM
Mar-31-23 11:44AM
Mar-30-23 04:16PM
03:25PM
07:00AM
Mar-25-23 10:17AM
Mar-21-23 04:05PM
Mar-13-23 09:00AM
Mar-01-23 04:05PM
Feb-28-23 07:45PM
04:05PM
09:00AM
Feb-27-23 04:40PM
08:00AM
Feb-23-23 08:00AM
Feb-21-23 08:29PM
Feb-14-23 09:00AM
Feb-07-23 09:00AM
Feb-02-23 05:17AM
Jan-20-23 05:12PM
Jan-18-23 09:00AM
Dec-23-22 06:48AM
Dec-15-22 07:37PM
07:00AM
Dec-14-22 07:22PM
04:10PM
01:44PM
12:10PM
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVIN ARTHUR ADirectorMay 20 '24Option Exercise1.245,0006,20019,830May 21 05:05 PM
LEVIN ARTHUR ADirectorMay 20 '24Sale29.905,000149,48114,830May 21 05:05 PM
MacLean Michael FChief Financial OfficerMay 14 '24Option Exercise8.8275,000661,500119,093May 16 06:25 PM
MacLean Michael FChief Financial OfficerMay 14 '24Sale28.2875,0002,121,04544,093May 16 06:25 PM
Boyce SarahPresident and CEOMay 07 '24Option Exercise1.2428,00034,720140,117May 07 09:52 PM
Boyce SarahPresident and CEOMay 07 '24Sale25.5428,000715,050112,117May 07 09:52 PM
LEVIN ARTHUR ADirectorApr 19 '24Option Exercise1.245,0006,20019,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 19 '24Sale22.825,000114,12314,830Apr 22 05:28 PM
LEVIN ARTHUR ADirectorApr 03 '24Sale27.1120,000542,214253,872Apr 03 08:26 PM
Boyce SarahPresident and CEOApr 02 '24Option Exercise1.2428,00034,720140,117Apr 03 06:16 PM
Boyce SarahPresident and CEOApr 02 '24Sale26.2528,000734,919112,117Apr 03 06:16 PM
LEVIN ARTHUR ADirectorMar 19 '24Option Exercise1.245,0006,20019,830Mar 21 04:10 PM
LEVIN ARTHUR ADirectorMar 19 '24Sale23.975,000119,84814,830Mar 21 04:10 PM
MacLean Michael FChief Financial OfficerMar 13 '24Option Exercise8.8240,000352,80084,093Mar 15 04:12 PM
MacLean Michael FChief Financial OfficerMar 13 '24Sale24.5240,000980,76044,093Mar 15 04:12 PM
Boyce SarahPresident and CEOMar 12 '24Option Exercise1.2428,00034,720140,117Mar 12 05:29 PM
LEVIN ARTHUR ADirectorMar 12 '24Option Exercise1.2425,00031,00042,471Mar 12 08:41 PM
Boyce SarahPresident and CEOMar 12 '24Sale22.6328,000633,682112,117Mar 12 05:29 PM
LEVIN ARTHUR ADirectorMar 12 '24Sale22.0327,641609,01714,830Mar 12 08:41 PM
Boyce SarahPresident and CEOMar 08 '24Option Exercise1.2484,000104,160196,117Mar 12 05:29 PM
Boyce SarahPresident and CEOMar 08 '24Sale21.3984,0001,796,710112,117Mar 12 05:29 PM
Boyce SarahPresident and CEOMar 01 '24Option Exercise1.2484,000104,160196,117Mar 05 04:53 PM
Boyce SarahPresident and CEOMar 01 '24Sale20.1384,0001,691,306112,117Mar 05 04:53 PM
Boyce SarahPresident and CEOJan 22 '24Sale10.135,09251,58244,008Jan 23 03:13 PM
Flanagan W. MichaelCSTOJan 22 '24Sale10.134,12941,82735,871Jan 23 03:12 PM
McCarthy TeresaChief Human Resources OfficerJan 22 '24Sale10.132,06520,91817,035Jan 23 03:11 PM
LEVIN ARTHUR ADirectorJan 22 '24Sale10.131,85918,83217,471Jan 23 03:14 PM
MacLean Michael FChief Financial OfficerJan 22 '24Sale10.131,61616,37016,884Jan 23 03:11 PM